Reliability and validity of the Personal and Social Performance scale in patients with schizophrenia

Schizophrenia Research

Volumn 140, Issue 1-3, 2012, Pages 71-76

  Nafees, Beenish ^a   van Hanswijck de Jonge, Patricia ^b   Stull, Donald ^b   Pascoe, Katie ^c   Price, Martin ^c   Clarke, Amory ^d   Turkington, Douglas ^e  

^a ICON PLC   (United Kingdom)

^b UNITED BIOSOURCE CORPORATION   (United States)

^c Janssen Cilag Ltd   (United Kingdom)

^d SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^e NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Patient reported outcomes; Personal and Social Performance scale; Schizophrenia; Social functioning

Indexed keywords

ADULT; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONSTRUCT VALIDITY; DISEASE SEVERITY; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; INTERNAL CONSISTENCY; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PERSONAL AND SOCIAL PERFORMANCE SCALE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; QUALITY OF LIFE; SCHIZOPHRENIA; SENSITIVITY ANALYSIS; SOCIAL INTERACTION; TEST RETEST RELIABILITY; UNITED KINGDOM;

EID: 84865331253     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2012.06.013     Document Type: Article

References (41)

1. Bell M., Lysaker P., Milstein R., et al. Concurrent validity of the cognitive component of schizophrenia: relationship of PANSS scores to neuropsychological assessment. Psychiatry Res. 2004, 54:51-58.
2. Bergner M., Bobbitt R.A., Carter W.B., et al. The Sickness Impact Profile: development and final revision of a health status measure. Med. Care 1981, 19(8):787-805.
3. Bodlund O., Kullgren G., Ekselius L., et al. Global Assessment of Functioning Scale: evaluation of a self-report version. Acta Psychiatr. Scand. 1994, 90:342-347.
4. Bow-Thomas C.C., Velligan D.I., Miller A.L., et al. Predicting quality of life from symptomatology in schizophrenia at exacerbation and stabilization. Psychiatry Res. 1999, 86(2):131-142.
5. Caldecott-Hazard S., Hall R.C. Outcome assessment in depressed hospitalised patients. J. Fla. Med. Assoc. 1995, 82:24-29.
6. Chanpattana W., Kramer B.A. Acute and maintenance ECT with flupenthixol in refractory schizophrenia: sustained improvements in psychopathology, quality of life, and social outcomes. Schizophr. Res. 2003, 63(1-2):189-193.
7. Cramer J.A., Rosenheck R., Xu W., et al. Quality of life in schizophrenia: a comparison of instruments. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. Schizophr. Bull. 2000, 26(3):659-666.
8. Cramer J., Rosenheck R., Xu W., et al. Detecting improvement in quality of life and symptomatology in schizophrenia. Schizophr. Bull. 2001, 27(2):227-234.
9. Davidson M., Emsley R., Kramer M., et al. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr. Res. 2007, 93:117-130.
10. Endicott J., Spitzer R.J., Fleiss J.L., et al. The Global Assessment Scale. a procedure for measuring overall severity of psychiatric disturbance. Arch. Gen. Psychiatry 1976, 33:366-371.
11. Gagnon D.D., Nasrallah H., Morosini P.-L. Reliability, validity and sensitivity to change of the personal and social performance scale in patients with stable schizophrenia. Int. J. Neuropsychopharmacol. 2006, 9(Suppl. 1):S288.
12. Gigantesco A., Vittorielli M., Pioli R., et al. The VADO approach in rehabilitation: a randomised control trial. Psychiatr. Serv. 2006, 57(12):1778-1783.
13. Goldman H.H., Skodol A.E., Lave T.R. Revising axis V for DSM-IV: a review of measures of social functioning. Am. J. Psychiatry 1992, 149(9):1148-1156.
14. Good K., Rabinowitz J., Whitehorn D., et al. The relationship of neuropsychological test performance with the PANSS in antipsychotic naive, first-episode psychosis patients. Schizophr. Res. 2004, 68:11-19.
15. Guy W. ECDEU Assessment Manual for Psychopharmacology 1976, revised version, US Department of Health, Education and Welfare, Bethesda, Maryland.
16. Haro J.M., Kamath S.A., Ochoa S., et al. The Global Impression-Schizophrenia Scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr. Scand. 2003, 107(416):16-23.
17. Heinrichs D.W., Hanlon E.T., Carpenter E.W. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr. Bull. 1984, 10:388-398.
18. Jarema M., Konieczynska Z. Quality of life in schizophrenia: impact of psychopathology, patients' gender and antipsychotic treatment. Int. J. Psychiatry Clin. Pract. 2001, 5(1):19-26.
19. Kane J., Canas F., Kramer M., et al. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr. Res. 2007, 90:147-161.
20. Kane J., Canas F., Kramer M., et al. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr. Res. 2007, 90(1-3):147-161. (Feb).
21. Kawata A.K., Revicki D.A. Psychometric properties of the Personal and Social Performance scale (PSP) among individuals with schizophrenia living in the community. Qual. Life Res. 2008, 17(10):1247-1256.
22. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13(2):261-276.
23. Kramer M., Simpson G., Maciulis V., et al. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. J. Clin. Psychopharmacol. 2007, 27:6-14.
24. Leuscht S., Engel R. The relative sensitivity of Clinical Global Impressions Scale and the Brief Psychiatric Rating scale in antipsychotic drug trials. Neuropsychopharmacology 2006, 31:406-412.
25. Leuscht S., Lasser R. The concepts of remission and recovery in schizophrenia. Pharmacopsychiatry 2006, 38:161-170.
26. Marder S.R., Kramer M., Ford L., et al. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol. Psychiatry 2007, 62(12):1363-1370.
27. McGrath J., Saha S., Chant D., et al. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol. Rev. 2008, 30(1):67-76.
28. Mike J., Bendix S. The concurrent validity of the Global Assessment of Functioning (GAF). Br. J. Clin. Psychol. 2002, 41:417-422.
29. Morosini P.L., Magliano L., Brambilla L., et al. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr. Scand. 2000, 101(4):323-329.
30. Nasrallah H., Morosini P., Gagnon D.D. Reliability, validity and ability to detect change of the Personal and Social Performance scale in patients with stable schizophrenia. Psychiatry Res. 2008, 161(2):213-224.
31. National Institute for Health and Clinical Excellence Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Adults in Primary and Secondary Care (Update) 2009, March.
32. Patrick D., Morosini P.-L., Rothman M. Reliability, validity and sensitivity to change of the personal and social performance scale in patients with acute schizophrenia. Int. J. Neuropsychopharmacol. 2006, 9(Suppl. 1):S287-S288.
33. Patrick D.L., Burns D., Morosini P.L., et al. Reliability, validity and ability to detect change of the clinician-rated Personal and Social Performance scale in patients with acute symptoms of schizophrenia. Curr. Med. Res. Opin. 2009, 25(2):325-338.
34. Rabinowitz J., Mehnert A., Eardekens M. To what extent do the PANSS and CGI-S overlap?. J. Clin. Psychopharmacol. 2006, 26:303-327.
35. Revicki D.A. Pharmacoeconomic studies of atypical antipsychotic drugs for the treatment of schizophrenia. Schizophr. Res. 1999, 35:S101-S109.
36. Roy-Byrne P., Dagadakis C., Unutzer J., et al. Evidence for limited validity of the revised Global Assessment of Functioning Scale. Psychiatr. Serv. 1996, 47:864-866.
37. Sartorius N. Fighting schizophrenia and its stigma. A new World Psychiatric Association educational programme. Br. J. Psychiatry 1997, 170:297.
38. Shrout P.E., Fleiss J.L. Intraclass correlations: uses in assessing rater reliability. Psychol. Bull. 1979, 2:420-428.
39. Turkington D., Kingdon D., Bryant C. Optimising functional outcome in schizophrenia: combining cognitive behavioural therapy with antipsychotic therapy. Prog. Neurol. Psychiatry 2007, 11(Suppl. 6):S10-S14.
40. Ware J.E., Sherbourne C.D. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med. Care 1992, 30(6):473-483.
41. Wilkinson G., Hesdon B., Wild D., et al. Self-report quality of life measure for people with schizophrenia: the SQLS. Br. J. Psychiatry 2000, 177:42-46.